Skip to main content
. Author manuscript; available in PMC: 2024 Mar 1.
Published in final edited form as: J Med Virol. 2023 Mar;95(3):e28673. doi: 10.1002/jmv.28673

Figure 6.

Figure 6.

Competition of 17A7, 17B10 and 3A6 mAbs with human COVID-19 convalescent sera or mRNA post-vaccination sera for binding to immobilized original RBD. (A) Schematic illustration of competition between mouse mAbs and human COVID-19 specific polyclonal sera. The % of residual (B) 17A7, (C) 17B10 or (D) 3A6 after competing with human COVID-19 convalescent sera or post-vaccination sera as compared to the wells that contained only mAbs were plotted by nonlinear regression. Data are expressed as mean ± s.e.m (n = 6–8 sera/group).